Are there clinical trials for ERG protein research in prostate cancer?

Question

I have stage IIIB prostate cancer and stay updated on research that might lead to new treatments. I recently read about exciting research on ERG, a protein involved in about half of all prostate cancers. The study found that ERG works by transforming one type of prostate cell (basal cells) into the cancer cells that make up most tumors (luminal cells). The researchers identified specific proteins like STAT3 and enzymes KMT2A and DOT1L as potential targets for future drugs. This could lead to treatments that target cancer at its source rather than just treating existing tumors. I'm interested in clinical trials and wondering if this research might open new opportunities.

• Have any of you participated in trials targeting ERG or similar pathways?
• What has your experience been with treatments that work differently than standard approaches?

Link: https://www.foxchase.org/news/researchers-uncover-how-key-oncogene-drives-prostate-cancer-its-earliest-stage

Outcomes4Me · Accepted Answer

Clinical trials targeting ERG and related pathways are still in early stages, as this research represents a newer understanding of how prostate cancer develops. Many community members have found value in discussing emerging research with their oncology teams to understand which trials might be relevant to their specific situation. The research on targeting proteins like STAT3 and enzymes KMT2A and DOT1L shows promise for future treatment approaches that could work differently than current standard therapies, and staying informed about these developments can help with treatment planning conversations with healthcare providers.

Are there clinical trials for ERG protein research in prostate cancer?

Related Questions